Selexipag: A New Treatment Agent for Pulmonary Arterial Hypertension

Journal Title: Meandros Medical and Dental Journal - Year 2019, Vol 20, Issue 1

Abstract

Pulmonary arterial hypertension (PAH) is a rare disease which is characterized by the progressive increase of pulmonary arterial pressure. PAH can lead to right cardiac insufficiency and death. Conventional and other treatment modalities that target the physiopathological and etiopathological causes of the disease are currently being used. Selexipag is an oral selective prostacyclin receptor agonist which was developed to overcome the pathophysiological mechanisms that play role in the PAH.

Authors and Affiliations

Onur Yazıcı, Hasan Güngör

Keywords

Related Articles

Non-surgical Root Canal Retreatment: A Retrospective Outcome Study

Objective: When the prognosis of a root canal treated (RCT) teeth is poor, retreatment (RT) of the former RCT is indicated. The aim of this study was to assess the long-term success rate of nonsurgical retreatment for fi...

Effect of Poly(Methyl Vinyl Ether-comaleic Anhydride) Copolymer on Bond Strength of Experimental Dental Adhesive

Objective: The contents of adhesive systems directly affect their bond strength. The purpose of this in vitro study was to evaluate the bond strength of experimental two-step self-etch (SE) adhesive containing Poly(methy...

The Influence of Iron Supplementation on Tooth Eruption of the Newborn

Objective: Iron is needed for many enzymes to function normally, so a wide range of symptoms may eventually emerge in iron deficiency, including retardations in growth and maturation. Because of this it is reasonable to...

Ultrasonographically Diagnosed Bicipital Fasciitis: The Importance of Ultrasonography for Early Diagnosis and Emphasis on Aseptic Technique

Here, we present a case of bicipital fasciitis after intraarticular injection of the shoulder joint. Bicipital fasciitis was diagnosed using real-time ultrasonography. The infection was probably due to non-compliance wit...

The Relationship Between Monocyte Count to High-density Lipoprotein Ratio and Severity of Inflammation in Aggressive Periodontitis: A Retrospective Analysis

Objective: Hyperlipidemia is a known cardiovascular disease risk factor. A common biological mechanism between systemic diseases, such as cardiovascular diseases, and periodontal diseases has been suggested. This study a...

Download PDF file
  • EP ID EP48900
  • DOI 10.4274/meandros.galenos.2017.20592
  • Views 342
  • Downloads 0

How To Cite

Onur Yazıcı, Hasan Güngör (2019). Selexipag: A New Treatment Agent for Pulmonary Arterial Hypertension. Meandros Medical and Dental Journal, 20(1), -. https://europub.co.uk/articles/-A-48900